ALX Oncology: Evorpacept For ASPEN-09 Presses On With 2 Key Milestones

Terry ChrisomalisInvesting Group LeaderFollow5ShareSavePlay(15min)CommentsSummaryALX Oncology is downgraded from 'strong buy' to 'hold' due to underperformance in the intent-to-treat HER2-positive gastric cancer population.ALXO pivots to targeting HER2-positive cancer patients with high CD47 expression, supported by prior studies showing higher ORR in this subgroup.Phase 2 ASPEN-09-Breast trial expands enrollment to 120 patients, with topline data expected mid-2027; biomarker-driven strategy may enhance response prediction.A recent $140.4M capital raise extends the cash runway into H1 2028, supporting ongoing trials and strategic repositioning.Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More »Thicha Satapitanon/iStock via Getty Images The last time I spoke about ALX Oncology (ALXO) it was with respect to a Seeking Alpha article entitled "ALX Oncology: On Right Track With Latest Interim Analysis Of Evorpacept". TheThis article was written byTerry Chrisomalis14.78K FollowersFollowTerry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his Applied Science background to generate long term value from Healthcare. He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to help Healthcare investors make informed decisions.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.